CARsgen Therapeutics Holdings Limited (HKG:2171)
12.00
-0.06 (-0.50%)
Oct 21, 2026, 4:08 PM HKT
CARsgen Therapeutics Holdings Employees
CARsgen Therapeutics Holdings had 424 employees as of June 30, 2026. The number of employees increased by 69 or 19.44% since the number was reported on December 31, 2025. That makes CARsgen Therapeutics Holdings the 21,320th largest employer in the world and 1,378th in Hong Kong.
Employees
424
Change
69
Growth
19.44%
Revenue / Employee
371.99K HKD
Profits / Employee
-242.83K HKD
Market Cap
6.75B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 424 | 69 | 19.44% | 424 | 0 |
| Dec 31, 2025 | 355 | -110 | -23.66% | 355 | 0 |
| Dec 31, 2024 | 465 | -51 | -9.88% | 465 | 0 |
| Dec 31, 2023 | 516 | -31 | -5.67% | 516 | 0 |
| Dec 31, 2022 | 547 | -26 | -4.54% | 539 | 8 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 1,999 |
| Lepu Biopharma | 646 |
| Alphamab Oncology | 515 |
| Suzhou Ribo Life Science | 453 |
| HBM Holdings | 327 |
| Ascletis Pharma | 217 |
| CStone Pharmaceuticals | 147 |
| LongBio Pharma (Suzhou) | 94 |
CARsgen Therapeutics Holdings News
- 2 months ago - CARsgen Therapeutics Announces 2026 Interim Results - PRNewsWire
- 4 months ago - CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors - PRNewsWire
- 4 months ago - China approves CARsgen's CAR-T treatment to treat stomach cancer - Reuters
- 4 months ago - CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026 - PRNewsWire
- 4 months ago - Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting - PRNewsWire
- 7 months ago - CARsgen Therapeutics Announces 2025 Annual Results - PRNewsWire
- 8 months ago - CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai - PRNewsWire
- 9 months ago - CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors - PRNewsWire